Lit Review: Modern Burn Care Innovation Outcomes

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Lit Review: Modern Burn Care Innovation Outcomes

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.

This episode examines innovative therapeutic approaches for treating severe thermal burns, focusing on reducing the need for traditional autografting. One study highlights the safety and efficacy of StrataGraft, a bioengineered skin substitute that successfully promoted wound closure in a majority of adult patients with deep partial-thickness burns. Another research paper compares the outcomes of using autologous skin cell suspensions (ASCS) with different dressing types, specifically evaluating contact layer dressings against poly-lactic acid dressings (PLAD). The findings indicate that utilizing PLAD alongside cell suspensions significantly lowers infection rates, shortens hospital stays, and reduces overall medical costs. Together, these articles suggest that advancing skin substitute technology and optimizing post-surgical dressings can improve clinical recovery while sparing healthy donor skin. This collective research underscores a shift toward biosynthetic solutions that simplify burn management and enhance patient outcomes in real-world medical settings. DISCLAIMER The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns. DONOR-SPARING COVERAGE FOR DEEP PARTIAL-THICKNESS AND LARGE BURNS STUDY GUIDE TOP TEN TAKEAWAYS 1. StrataGraft is a bioengineered bilayer construct used as a single application on deep partial-thickness (DPT) burns that still have intact dermal elements, with the explicit goal of avoiding or minimizing autograft harvest. 2. In the StrataCAT expanded-access cohort (n = 52; 3–50% TBSA), 88.5% of patients achieved complete wound closure without additional autografting; only 11% needed partial autograft at incomplete sites. 3. Confirmed closure by week 12 occurred in 63.5% of patients (71.9% of treatment sites); durable closure by week 24 occurred in 55.8% of patients (60.4% of sites). 4. Safety was consistent with ordinary burn-unit morbidity: 88.5% had at least one TEAE (most often mild pruritus); 19.2% had serious TEAEs, none attributed to StrataGraft; four deaths were unrelated. 5. Prior RCTs (STRATA2011, STRATA2016) already showed that most DPT wounds treated with StrataGraft needed no autograft by day 28 and closed at rates comparable to autograft by month 3; StrataCAT extends that experience into a real-world, broader-access population. 6. Autologous skin cell suspension (ASCS) expands a small thin donor harvest at approximately 1:80 and can be used alone or with split-thickness skin graft (STSG) on larger TBSA injuries. 7. The kit’s default contact-layer dressing (CLD) is prone to poor adherence, fluid pooling, and infection; a poly-lactic acid biosynthetic dressing (PLAD) adheres more closely, permits fluid egress, and functions as a temporary epithelial barrier. 8. In a single-center before-after cohort of ≥10% TBSA burns treated with ASCS (± STSG), PLAD versus CLD was associated with shorter length of stay (17 vs 29 days) and fewer postoperative wound infections (approximately 7–9% vs 32–39%). 9. After adjustment for grafted area and TBSA, CLD carried an 8-fold higher odds of postoperative infection; antibiotic days were also substantially shorter with PLAD (0.47 vs 4.39 days). 10. Inflation-adjusted charges per %TBSA trended lower with PLAD ($18,459 vs $25,396); the biologic dressing therefore functions as both a clinical and a resource intervention, not merely a coverage layer. STUDY GUIDE I. StrataGraft for Deep Partial-Thickness Burns with Intact Dermis Autograft remains the reference standard for definitive closure of deep burns, but donor-site morbidity—pain, infection, hypertrophic scar, and limited harvestable skin in the elderly or the thin-skinned—creates a standing need for donor-sparing alternatives. StrataGraft is a bioengineered, bilayered skin substitute applied as a single, meshed (≤1:1) sheet to DPT wounds that retain dermal elements. Earlier controlled studies (STRATA2011 Phase 1b, n = 30; STRATA2016 Phase 3, n = 71) established that most treated sites required no autograft by day 28 and that three-month closure rates approximated those of autograft, with a TEAE profile typical of burned patients. A. StrataCAT design StrataCAT (NCT04123548) was a Phase 3b, open-label, single-arm, multicenter expanded-access study intended to maintain product availability after the pivotal trials and to enlarge real-world safety experience. Fifty-two adults with 3% to less than 50% TBSA thermal burns received one application of StrataGraft and were followed for 24 weeks. The primary endpoint was the count and percentage of patients with treatment-emergent adverse events. Efficacy endpoints (confirmed and durable ...

Ancora nessuna recensione